Dewpoint Therapeutics
Phi is a Texas native where he received a BS in microbiology from UT Austin in 2006. He completed his PhD in biochemistry at UT Southwestern investigating the structure and kinetic mechanisms of AMPylator enzymes. Phi’s postdoctoral research at Boston Children’s contributed to mechanistic and chemogenomic efforts in the field of biomolecular condensates, inflammatory bowel disease and the biological networks of intracellular trafficking. At Dewpoint he is continuing his interests in condensate biology to help uncover its mysteries and develop treatments to improve human lives.
Dewpoint Therapeutics
Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions has pathways that are regulated by condensates or arise from the dysfunction of condensates - including cancer, neurodegeneration, and metabolic disease.